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Recurrent LDL-receptor
mutation causes familial
hypercholesterolaemia in
South African coloureds
and Afrikaners
M. J. Kotze, E. Langenhoven, L. Theart, O. Loubser,
A. Micklem, C. J. J. Oosthuizen
Three IOW-density lipoprotein receptor (LDLR) gene
mutations were previously shown to cause familial
hypercholesterolaemia (FH) in up to 90% of affected
Afrikaners. Association of each mutation with a single
chromosomal background provided molecular genetic
evidence that the proposed 'founder gene effect' was
responsible for the high prevalence of FH among white
Afrikaners. In this study we report the identification of the
FH Afrikaner-2 (FH2) mutation, Val408 to Met, in the so-
called coloured population of South Africa, a people of
mixed ancestry, with rapid non-radioactive methods for
mutation detection. Haplotype analysis with
polymorphisms on both sides of the FH2 mutation
indicated that the identical LDLR gene mutations found in
two different South African population groups were
caused by independent events at a potential CpG
mutational 'hot spot'. The allelic variation giving rise to the
different chromosomal backgrounds of the FH2 mutation
does not affect the properties of the abnonnal LDLR
protein product which causes FH in these SUbjects. This
mutation is thus expected to cause the same severe fonn
of FH in affected coloureds as was previously
demonstrated in Afrikaners. Detection of mutant LDLR
gene alleles in polymerase chain reaction products,
directly after gel electrophoresis, now allows accurate
presymptomatic diagnosis of the FH2 mutation in FH
patients from two different South African population
groups.
S Atr Med J 1995; 85: 357-361.
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Familial hypercholesterolaemia (FH) contributes significantly
to the high mortality from coronary heart disease (CHD) in
several South African populations. Since more than 150
different naturally occurring low-density lipoprotein receptor
(LDLR) gene mutations have been described to date,' direct
molecular diagnosis of FH is currently limited
to genetically homogeneous populations, where the majority
of individuals carry only a few disease related mutations.
In such populations, like the South African Afrikaners2-4 and
Ashkenazi Jews,' specific founder gene defects can be
diagnosed accurately. In the Afrikaner population it has been
shown that three LDLR gene mutations cause FH in
approximately 90% of affected individuals.'·7 Although each
founder-related mutation was found to be associated with a
single chromosomal background in the Afrikaner patients
analysed:'· subsequent screening of Dutch FH patients for
these mutations revealed a second haplotype associated
with the FH Afrikaner-2 (FH2) mutation, Val<aa to Met.9 In this
study we identified the FH2 mutation on a third haplotype in
two unrelated individuals of mixed ancestry, using direct
non-radioactive molecular methods that are more
convenient than those previously described, which involve
the use of radioactivity and/or expensive restriction
enzymes.'.7
Materials and methods
Analysis of the FH Afrikaner-2 mutation
DNA samples of individuals, previously typed by
hybridisation with allele-specific oligonucleotides for the
absence or presence of the FH2 mutation (Val<aa to Met, G to
A mutation at base 1285 in exon 9 of the LDLR gene)' were
used to standardise detection of the mutation with the
amplification refractory mutation system (ARMS)" and single-
strand conformation polymorphism (SSCP) method." SSCP
analysis was performed on polymerase chain reaction (PCR)
products amplified with exon 9-specific oligonucleotides
N2 (5'-GCTCCATCGCCTACCTCTIC-3') and A2 (5'-
GCTCACCTGCAGATCATICTCTGGG-3') as described
previously! Aliquots of the 172 bp amplified products (5 ~1)
were denatured with alkali (0,5M NaOH, 10 mM EDTA) at
42°(; for 5 minutes, electrophoresed at 80 V overnight at
room temperature in a non-denaturing 10% polyacrylamide
gel supplemented with 5% glycerol, and stained with
ethidium bromide (0,5 ~g ml-') for 10 minutes. Reactions for
the ARMS analysis were performed in two separate tubes per
sample, each containing one allele-specific oligonucleotide,
9.6 (5'-AGCCTCATCCCCAACCTGAGGAQCG-3', normal
allele) or 9.7 (5'-AGCCTCATCCCCAACCTGAGGACCA-3'
mutant allele), in conjunction with a common dist~prime~ A2
(see above). The underlined base was deliberately
destabilised to ensure allele-specificity. Primers specific for
exon 26 of the apolipoprotein (apo) B gene,,2 AB-1
(5'-GGAGCAGTIGACCACAAGCTIAGC-3') and AB-2
(5'-CAGGGTGGCTTIGCTIGTATGTIC-3'), were included in
all reactions and served to provide an internal control PCR
product of 345 bp. Approximately 0,5 I-Ig genomic DNA were
used in the amplification reaction, with 5 pmol of each primer
and one unit Taq DNA polymerase in a volume of 50 ~1. Taq
DNA polymerase, exclusively from Boehringer Mannheim,
was used in the ARMS assay, since unacceptable
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nonspecific bands were obtained when amplification was
performed with Taq polymerase purchased from some other
manufacturers. The four deoxynucleoside triphosphates were
each added to 100 ~M in 1 x Taq DNA polymerase buffer
(Boehringer Mannheim). Reaction mixtures were overlaid with
light mineral oil (Sigma, 50 ~I), subjected to DNA
denaturation at 94°C for 5 minutes and then to 30 cycles of
amplification (93°C for 1 minute; 60°C for 1 minute; 72°C for
2 minutes). PCR products were analysed in 2% agarose gels.
Subjects
The ARMS method described above was used to identify
the FH2 mutation in 2 coloured and 28 Afrikaner FH patients.
unrelated to the second degree. A total of 24 family
members were also screened for the FH2 mutation with
either the ARMS or SSCP method. Patients attended the
lipid clinic at Tygerberg Hospital, or were referred for DNA
analysis of FH from other lipid clinics in South Africa,
general practitioners or the Department of National Health.:
and Population Development.
Haplotype analysis
Haplotypic arrangements at 14 polymorphic sites within or
closely linked to the LDLR gene were analysed: the ApaLl
restriction fragment length polymorphism (RFLP) in intron
3,13 the Taql RFLP in intron 4,14 the Sphl RFLP in intron 6,15
the Smal RFLP in intron 7.,'6 the Stul RFLP in exon 8,17 the
guanine to adenine base change in exon 10,'6 the Hincll
RFLP in exon 12,'9 the BstEII RFLP in intron 12,2°':11 the Avail
RFLP in exon 13,22 the Pvull RFLP in intron 15,23 the Ncol
RFLP in exon 18,24 the two Mspl RFLPs in exon 18:5 and the
3'-flanking Pstl RFLp'26 Genotypes at tRe polymorphic sites
in introns 4 and 7, and exons 8, 10, 12, 13 and 18 were
determined by PCR-based methods, while the others were
analysed by Southern blot analysis.
FH-associated haplotypes for all subjects were deduced
by segregation analysis, based on the assumption that there
were no recombination events within families, or by
homozygosity for the polymorphisms analysed.
Results
Fig. 1 shows the allelic differentiation 0btained with the
ARMS and SSCP methods respective!Jy, directly after PCR
amplification and gel electrophoresis of genomic DNA from
normal individuals, heterozygotes and,homozygotes for the
FH2 mutation of the LDLR gene. Wheh the ARMS method
was used on the DNA of a normal indivi.dual, a product was
derived only from the internal control primers and primers
9.6 and A2 (Fig. 1A, lane 1). No LDLR gene product (or very
faint bands) was observed when primer 9.7, specific for the
mutant allele, replaced primer 9.6 (lane 2). When DNA of a
FH2 heterozygote was used in the two separate reactions,
the expected 100 bp fragment was generated when either
primer 9.6 or 9.7 was included in the reaction (Fig. 1A, lanes
3 and 4). Amplification occurred with DNA from a FH2
homozygote only when the mutant oligonucleotide was used
(lane 6). Presence of the 345 bp apo B fragment (internal
control) in all tubes indicated that amplification occurred in
all the reactions. SSCP analysis was performed on the same
•
set of DNA samples, as well as on some additional samples,
to test the mutation-detection efficiency of this method for
the FH2 mutation. In Fig. 1B the G alleles in normal
individuals could readily be distinguished from the A alleles
in affected individuals.
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Table I. LDLR gene haplotypes associated with the FH2 mutation
in two different South African population groups
Polymorphism Location Afrikaner Mixed race
ApaLl Intron 3 + +
Taql Intron 4
Sphl Intron 6 + +
Smal Intron 7 +
Stul Exon 8 + +
Exon 10 A A
Hincll Exon 12 + +
BstEII Intron 12
Avail Exon 13
Pvull Intron 15 +
Ncol Exon 18 +
Mspl Exon 18 +
Mspl Exon 18 +
Pstl 3' flanking
T. :::: presence ?f a restriction enzyme cutting site; - :::: absence of a restriction enzyme cutting
site; A =ademne; G =guanine.
Fig. 1. Analysis of the FH2 mutation after PCR amplification and
gel electrophoresis. (A) ARMS analysis of a normal control (lanes
1 - 2), a FH heterozygote (lanes 3 - 4) and a FH homozygote
(lanes 5 - 6). ARMS primers were used as follows: lanes 1, 3 and
5, normal G-allele (9.6); lanes 2, 4 and 6, mutant A-allele (9.7).
These ~ere used in conjunction with a common distal primer
(A2). Primers AB-1 and AB-2, producing PCR products of 345 bp,
were used in each reaction as internal controls. PCR products
were electrophoresed in 2% agarose gels. (B) Non-isotopic SSCP
analysis of alkali-denatured PCR products of 172 bp on 10%
acrylamide gels containing 5% glycerol. Lanes: (1) 1 kb DNA
ladder, (2) undenatured DNA control, (3 - 5) DNA from normal
controls, (6 - 7) DNA from FH patients heterozygous for the FH2
mu~ation and (8) DNA from a FH homozygote. (bp =base pairs; ss
=single-stranded DNA; ds =double-stranded DNA)
The above methods were used to identify 30 FH2
heterozygotes during an ongoing screening of South African
patients for known LDLR gene mutations. Subsequent
genotyping at 14 polymorphic sites showed that the FH2-
associated haplotype in two unrelated coloured families
differs from that in Afrikaners at 5 polymorphic sites framing
the FH2 mutation. Table I compares the different
polymorphic alleles associated with the FH2 mutation in the
Afrikaner and coloured populations. None of the South
African FH2 heterozygotes studied showed disease-
association with the second haplotype described in Dutch
patients!
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Discussion
Three founder-related LDLR gene·mutations increased the
prevalence of FH among Afrikaners to about 1 in 80,27
compared with 1 in 500 in most other population groups.
One of these, the so-called FH2 mutation, causes a severe
phenotype2• and accounts for FH in about 20% of
Afrikaners.· In this study we applied non-radioactive ARMS
and/or SSCP methods to screen for the FH2 mutation in
hypercholesterolaemics who were referred to us for a DNA
diagnosis of FH.29 By utilising the exon 9-specific PCR
amplification primers, described previously, for analysis of
the FH2 mutation by differential oligonucleotide
hybridisation," we obtained reprodUcible results by direct
visualisation of different alleles after electrophoresis in SSCP
gels and ethidium bromide staining. 30 Direct analysis of the
FH2 mutation, following allele-specific amplification by the
ARMS method and gel electrophoresis, required synthesis of
primers specific for the mutant and normal alleles for use in
two separate PCR reactions. When screening FH
heterozygotes we found a single PC"R reaction, using only
the mutant ARMS primers, to be adequate. The specificity of
the ARMS primers was increased by the introduction of an
additional mismatch near the 3' ends to avoid false-positive
results. False-negative results were excluded by the co-
amplification of a 345 bp PCR product of the apo B gene.
The apo B gene products obtained in the reactions can be
used simUltaneously to screen hypercholesterolaemics for
point mutations that cause familial defective apolipoprotein
8-100,31 by heteroduplex analysis in low cross-linking
polyacrylamide gels.32
Haplotype analysis in the normolipidaemic and FH
populations has previously shown the FH2 mutation to be
associated with a single 10-RFLP arrangement in
Afrikaners.· Subsequent screenin"g for the 3 Afrikaner
founder LDLR gene mutations in patients of Dutch descent
resulted in the identification of the FH2 mutation in 1,6% of
subjects! Of the 16 FH2 heterozygotes detected in the
Netherlands, 7 shared a LDLR gene haplotype with Afrikaner
patients. The remaining 9 patients had the same FH2
.~~======c:====
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mutation-associated haplotype, which was partly identical to
that in Afrikaners and could have arisen from a single
recombinational event. Genealogical and extended
haplotype studies support the hypothesis that the FH2
mutation originated in the Netherlands and was introduced
into South Africa by an early Dutch settler in the 17th
century (J. C. Defesche - personal communication and
unpublished results).
In this study the FH2 mutation was identified in 30 South
African patients who had not previously been analysed in
respect of the haplotype on which the mutation occurred.'
To investigate the relationship between the FH2 mutations
detected in both Afrikaner and coloured patients, we
performed haplotype analysis using 14 polymorphic sites at
the LDLR locus."'" As expected, the chromosomal
background originally described for the FH2 mutation'
showed an association with the mutation in the Afrikaner
patients, but a different disease-associated haplotype was
identified in two unrelated coloured patients. These
haplotypes differ on both sides of the mutation in exon 9: at
the Pvull, Ncol and two Mspl RFLPs on the 3' side and at
the Smal RFLP on the 5' side.
The above results suggest that independent mutational
events in exon 9 of the LDLR gene gave rise to the FH2
mutation in two different South African populations. The fact
that the single-base substitution in exon 9 involves a
methylated CpG dinucleotide,33 known to mutate frequently,"
further supports this theory. The FH2 mutation could,
however, also have had a common origin if the
chromosomal background were changed by a crossover
between the FH2 mutation in exon 9 and the Pvull
polymorphism in intron 15, and a base pair change occurred
at the Smal site. This possible, but improbable, mechanism
was excluded by haplotype analyses of normolipidaemic
coloureds (data not shown). Since the heterozygosity of
most RFLPs described earlier at the 5' end of the LDLR
gene is very IOW,'3,'4 conclusive evidence against the second
mechanism's giving rise to the different FH2 mutation-
associated haplotypes eame from an analysis of the
recently-described Smal RFLP in intron 7." The frequency of
this excellent LDLR gene haplotype marker is high in FH and
normal individuals from both population groups (data not
shown). These results provide evidence against the
possibility that the base pair change, that creates the Smal
site in the 'coloured' haplotype arose on an ancient FH2
mutation-associated haplotype that underwent a single
recombination event.
The historic ethnic origin of the FH2 mutation found in
coloureds was not investigated further. Whites, Asians and
blacks have contributed to the gene pool of the present-day
coloured population of South Africa.35 We do believe that, as
more FH patients in more population groups both in and
outside South Africa are genotyped at the disease locus,
further light will be shed on the origins of this mutation.
Although the properties of the abnormal LDLR are not
affected by the polymorphic sites that allow differentiation of
the chromosomal background for the FH2 mutation in the
two South African patient groups, the presence of a Pvull
site in coloureds may result in a more favourable genetic
background for the phenotypic expression of FH. This
neutral Pvull RFLP in intron 15, that is probably in linkage
disequilibrium with a functionally important sequence
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change in the LDLR gene, shows significant association with
cholesterol level variation in healthy individuals.",37 The effect
associated with the Pvull rare allele (+) is to lower total and
LDL-cholesterol levels, and its relatively higher frequency in
individuals over the age of 65 years suggests that the allele
may be associated with increased fitness for survival.37
Variability in the clinical expression of FH, due to the
influence of other genetic and non-genetic factors, has
previously been illustrated in South African patients with
identical mutant genes.38,39
Our findings confirm the previous assessment of a single
FH2 founder gene among Afrikaners,z,4" most probably
introduced into South Africa by a single individual of Dutch.
origin. Screening for the FH2 mutation and its associated
haplotypes in other South African population groups has
shown that this mutation is also common in people of mixed
racial ancestry as a result of an independent mutational
event. To date, 4 coloured FH2 heterozygotes have been~
identified, and in all of them the newly-described haplotype
was associated with the disease (A. D. Marais - personal
communication), Both non-radioactive methods described' in
this study facilitate rapid, inexpensive diagnosis of the-·FH2
gene mutation in hyperlipidaemic individuals. Previous
observations that this specific mutation causes considerably
elevated cholesterol levels and death at a young age
underline the potential importance of detecting FH2 patients
presymptomatically.9~,,39
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Research has shown substantial support for the thesis that
dietary intervention slows the progression of chronic renal
failure.'·3 Although renal function in earlier studies was based
on changes in serum creatinine (Sa). the protective effect of a
low-protein (LP) diet was confirmed by Ihle et al. 4 who used
Supplemented low-protein
diets - are they superior in
chronic renal failure?
Twenty-two patients with chronic renal failure were
randomly assigned to a conventional low-protein diet
containing 0,6 g protein/kg/day or a very-low-protein diet
containing 0,4 g protein/kg/day supplemented with
essential amino acids; they were followed up for 9 months.
There were no significant changes in body mass index,
arm muscle area,. percentage body fat, serum albumin and
transferrin levels in any of the groups; neither was there
any difference between the groups in, respect of these
parameters. Renal function, as measured by the reciprocal
of serum creatinine over time, stabilised in both groups
during intervention, with no significant difference between
the groups. There was however no correlation between
changes in renal function and changes in blood pressure,
or dietary intake of protein, phosphorus, cholesterol,
polyunsaturated and saturated fatty acids. There were also
no significant changes and no significant differences
between the groups in serum levels of parathyroid
hormone and alkaline phosphatase, urine cyclic adenosine
monophosphate, tubular reabsorption of phosphate, and
the theoretical renal threshold for phosphate.
The results of this study suggest that the supplemented
very-low-protein diet was not superior to the conventional
low-protein diet in terms of its effect on protein-energy
status, renal function and biochemical parameters of renal
osteodystrophy.
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